Barinthus Biotherapeutics Statistics

Total Valuation

BRNS has a market cap or net worth of $44.25 million. The enterprise value is -$50.19 million.

Market Cap	44.25M
Enterprise Value	-50.19M

Important Dates

The last earnings date was Wednesday, November 6, 2024, before market open.

Earnings Date	Nov 6, 2024
Ex-Dividend Date	n/a

Share Statistics

BRNS has 40.23 million shares outstanding. The number of shares has increased by 2.31% in one year.

Current Share Class	n/a
Shares Outstanding	40.23M
Shares Change (YoY)	+2.31%
Shares Change (QoQ)	+0.97%
Owned by Insiders (%)	9.32%
Owned by Institutions (%)	26.01%
Float	27.53M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	2.76
Forward PS	n/a
PB Ratio	0.26
P/TBV Ratio	0.35
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 8.93, with a Debt / Equity ratio of 0.08.

Current Ratio	8.93
Quick Ratio	8.43
Debt / Equity	0.08
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-1,301.04

Financial Efficiency

Return on equity (ROE) is -32.60% and return on invested capital (ROIC) is -20.52%.

Return on Equity (ROE)	-32.60%
Return on Assets (ROA)	-18.65%
Return on Capital (ROIC)	-20.52%
Revenue Per Employee	$115,146
Profits Per Employee	-$444,823
Employee Count	130
Asset Turnover	0.07
Inventory Turnover	n/a

Taxes

Income Tax	-867,000
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -70.19% in the last 52 weeks. The beta is -0.72, so BRNS's price volatility has been lower than the market average.

Beta (5Y)	-0.72
52-Week Price Change	-70.19%
50-Day Moving Average	1.15
200-Day Moving Average	1.63
Relative Strength Index (RSI)	53.49
Average Volume (20 Days)	36,945

Short Selling Information

Short Interest	5,321
Short Previous Month	13,924
Short % of Shares Out	0.02%
Short % of Float	n/a
Short Ratio (days to cover)	0.07

Income Statement

In the last 12 months, BRNS had revenue of $14.97 million and -$57.83 million in losses. Loss per share was -$1.49.

Revenue	14.97M
Gross Profit	-30.12M
Operating Income	-62.45M
Pretax Income	-65.25M
Net Income	-57.83M
EBITDA	-59.84M
EBIT	-62.45M
Loss Per Share	-$1.49

Full Income Statement

Balance Sheet

The company has $106.10 million in cash and $12.67 million in debt, giving a net cash position of $93.43 million or $2.32 per share.

Cash & Cash Equivalents	106.10M
Total Debt	12.67M
Net Cash	93.43M
Net Cash Per Share	$2.32
Equity (Book Value)	159.46M
Book Value Per Share	4.03
Working Capital	119.58M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$61.63 million and capital expenditures -$461,000, giving a free cash flow of -$62.09 million.

Operating Cash Flow	-61.63M
Capital Expenditures	-461,000
Free Cash Flow	-62.09M
FCF Per Share	-$1.54

Full Cash Flow Statement

Margins

Gross Margin	-201.19%
Operating Margin	-417.20%
Pretax Margin	-392.47%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

BRNS does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-2.31%
Shareholder Yield	-2.31%
Earnings Yield	-133.72%
FCF Yield	-143.58%

Analyst Forecast

The average price target for BRNS is $4.00, which is 263.64% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$4.00
Price Target Difference	263.64%
Analyst Consensus	Strong Buy
Analyst Count	2
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

BRNS has an Altman Z-Score of 0.08 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	0.08
Piotroski F-Score	1